Serum progastrin-releasing peptide in pneumonia, COPD, and early-stage lung cancers
Author Information
Author(s): Begolli Gramos, Lukić Maja, Rumora Lada, Čorak Lorna, Vukić Dugac Andrea, Jakopović Marko, Samaržija Miroslav, Tomaš Ilijan, Knežević Jelena, Debeljak Željko
Primary Institution: University Hospital Centre Zagreb
Hypothesis
The study aims to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD), and early-stage primary lung cancers.
Conclusion
ProGRP concentrations in pneumonia and COPD patients were higher than in early-stage lung cancer patients.
Supporting Evidence
- Median proGRP > 50 ng/L was measured in pneumonia and COPD.
- Median proGRP < 40 ng/L was measured in early-stage lung adenocarcinoma and squamous cell carcinoma.
- ProGRP concentrations were associated with CRP levels.
- ProGRP levels in pneumonia and COPD may exceed those in early-stage small-cell lung cancer.
Takeaway
This study found that patients with pneumonia and COPD have higher levels of a specific protein in their blood compared to those with early-stage lung cancer.
Methodology
An observational study comparing serum proGRP concentrations among patients with pneumonia, COPD, and early-stage lung cancers.
Potential Biases
The study design may limit the generalizability of the findings due to the specific patient population.
Limitations
The sample size is relatively low, and other causes of elevated serum proGRP were not analyzed.
Participant Demographics
{"age":{"pneumonia":"70 (47-90)","lung_cancer":"63 (43-78)"},"gender":{"male":{"pneumonia":67,"lung_cancer":78},"female":{"pneumonia":24,"lung_cancer":29}},"smoking_status":{"smoker":{"pneumonia":61,"lung_cancer":73},"non_smoker":{"pneumonia":28,"lung_cancer":34}}}
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website